Studying breast cancer samples during treatment before surgery
Collects breast cancer tissue and blood samples from adults before surgery during treatment.
Plain-language title generated from the registry record
Registry title: Breast Cancer Evolution During Neoadjuvant Systemic Therapy
Key facts
- Where
- London, United KingdomSee the site
Where in United Kingdom
- Royal Marsden NHS Foundation TrustLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Royal Marsden NHS Foundation Trust
- Trial code
- NCT06681064
- Record updated
- 16 April 2026
- Original description
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before surgery. In certain cases, MRI scans and stool samples will also be obtained before and during treatment. The samples collected from this study will be used for molecular and genetic research to understand why some cancers respond very well to anticancer treatments, and some do not, develop novel ways of accurately measuring response during treatment, as well as identify which patients are at a higher risk of the cancer coming back after surgery.Read full original descriptionShow less
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before surgery. In certain cases, MRI scans and stool samples will also be obtained before and during treatment. The samples collected from this study will be used for molecular and genetic research to understand why some cancers respond very well to anticancer treatments, and some do not, develop novel ways of accurately measuring response during treatment, as well as identify which patients are at a higher risk of the cancer coming back after surgery.
Inclusion: Histologically confirmed non-metastatic invasive breast cancer; Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy; If HER2-, suitable for treatment with upfront taxane chemotherapy. If HER2+, suitable for treatment with anti-HER2 targeted therapy; Be aged 18 years and over; Have given written informed consent to participate.
Exclusion: Treatment with neoadjuvant endocrine therapy only; Metastatic breast cancer at diagnosis; Presence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.